PL3440106T3 - T cell receptors - Google Patents

T cell receptors

Info

Publication number
PL3440106T3
PL3440106T3 PL17723016T PL17723016T PL3440106T3 PL 3440106 T3 PL3440106 T3 PL 3440106T3 PL 17723016 T PL17723016 T PL 17723016T PL 17723016 T PL17723016 T PL 17723016T PL 3440106 T3 PL3440106 T3 PL 3440106T3
Authority
PL
Poland
Prior art keywords
cell receptors
receptors
cell
Prior art date
Application number
PL17723016T
Other languages
Polish (pl)
Inventor
Nicholas TRIBBLE
William Lawrance
Eleanor BAGG
Original Assignee
Adaptimmune Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adaptimmune Limited filed Critical Adaptimmune Limited
Publication of PL3440106T3 publication Critical patent/PL3440106T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
PL17723016T 2016-04-08 2017-04-10 T cell receptors PL3440106T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201606177 2016-04-08
EP17723016.6A EP3440106B1 (en) 2016-04-08 2017-04-10 T cell receptors
PCT/EP2017/058580 WO2017174824A1 (en) 2016-04-08 2017-04-10 T cell receptors

Publications (1)

Publication Number Publication Date
PL3440106T3 true PL3440106T3 (en) 2022-01-31

Family

ID=58701592

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17723016T PL3440106T3 (en) 2016-04-08 2017-04-10 T cell receptors

Country Status (25)

Country Link
US (5) US11286289B2 (en)
EP (2) EP3440106B1 (en)
JP (2) JP7240176B2 (en)
KR (2) KR102747867B1 (en)
CN (2) CN116217703A (en)
AU (2) AU2017248122B2 (en)
BR (1) BR112018070625A2 (en)
CA (1) CA3020058A1 (en)
CY (1) CY1124664T1 (en)
DK (1) DK3440106T3 (en)
ES (1) ES2891321T3 (en)
HR (1) HRP20211493T1 (en)
HU (1) HUE056433T2 (en)
IL (1) IL262128B2 (en)
LT (1) LT3440106T (en)
MX (2) MX395611B (en)
PL (1) PL3440106T3 (en)
PT (1) PT3440106T (en)
RS (1) RS62623B1 (en)
RU (1) RU2018138838A (en)
SG (1) SG11201808751SA (en)
SI (1) SI3440106T1 (en)
SM (1) SMT202100564T1 (en)
WO (1) WO2017174824A1 (en)
ZA (2) ZA201806866B (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MA49156A (en) 2014-12-23 2020-03-25 Immatics Biotechnologies Gmbh NEW PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY FOR HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS
DK3440106T3 (en) 2016-04-08 2021-10-04 Adaptimmune Ltd T-CELL RECEPTORS
KR20190059874A (en) * 2016-04-08 2019-05-31 어댑티뮨 리미티드 T cell receptor
BR112018070637A2 (en) * 2016-04-08 2019-02-05 Adaptimmune Ltd t cell receptors
WO2019069125A1 (en) 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf Chimeric antigen receptors
CN109777778B (en) * 2017-11-14 2023-07-18 中国科学院广州生物医药与健康研究院 A Genetically Modified γδT Cell
GB201803750D0 (en) 2018-03-08 2018-04-25 Immunocore Ltd Method
GB201819540D0 (en) 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
EP3714941A1 (en) * 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
CA3139011A1 (en) * 2019-05-08 2020-11-12 Medigene Immunotherapies Gmbh Engineered t cells
PH12021553152A1 (en) * 2019-06-18 2022-08-15 Regeneron Pharma Mage-a4 t cell receptors and methods of use thereof
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
EP4004049A1 (en) 2019-07-24 2022-06-01 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors with mage-a4 specificity and uses thereof
AU2020327671A1 (en) 2019-08-13 2022-03-03 King's College London Immunoresponsive cells armoured with spatiotemporally restricted activity of cytokines of the IL-1 superfamily
KR20220100963A (en) 2019-12-18 2022-07-18 에프. 호프만-라 로슈 아게 Antibodies that bind to HLA-A2/MAGE-A4
WO2021144338A1 (en) * 2020-01-14 2021-07-22 Adaptimmune Limited Method of treatment of cancer or tumour
TWI890283B (en) 2020-02-14 2025-07-11 美商基利科學股份有限公司 Antibodies and fusion proteins that bind to ccr8 and uses thereof
GB202006903D0 (en) * 2020-05-11 2020-06-24 Adaptimmune Ltd Modified iPSCs
CA3183756A1 (en) 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
TW202406932A (en) 2020-10-22 2024-02-16 美商基利科學股份有限公司 Interleukin-2-fc fusion proteins and methods of use
MX2023010541A (en) * 2021-03-09 2023-11-24 Cdr Life Ag Mage-a4 peptide-mhc antigen binding proteins.
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
EP4091627A1 (en) 2021-05-21 2022-11-23 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for magea4-derived epitopes
EP4422651A4 (en) * 2021-10-25 2025-12-17 Univ Texas Modified Peptides and T Lymphocyte Receptors Targeting the MAGE-A4 Antigen and Methods of Use
AU2022375782B2 (en) 2021-10-28 2026-02-26 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
JP7787991B2 (en) 2021-10-29 2025-12-17 ギリアード サイエンシーズ， インコーポレイテッド CD73 compound
US12122764B2 (en) 2021-12-22 2024-10-22 Gilead Sciences, Inc. IKAROS zinc finger family degraders and uses thereof
KR20240123836A (en) 2021-12-22 2024-08-14 길리애드 사이언시즈, 인코포레이티드 Icarus zinc finger family decomposers and their uses
TW202340168A (en) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7 inhibitors
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN116836261A (en) * 2022-03-24 2023-10-03 香雪生命科学技术（广东）有限公司 High-affinity TCR (TCR) for recognizing MAGE-A4 antigen, and sequence and application thereof
GB202205572D0 (en) 2022-04-14 2022-06-01 Adaptimmune Ltd Engineered T cells
CR20240451A (en) 2022-04-21 2024-12-04 Gilead Sciences Inc Kras g12d modulating compounds
KR20250028371A (en) 2022-07-01 2025-02-28 길리애드 사이언시즈, 인코포레이티드 CD73 compound
CA3264474A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag Mage-a4 peptide dual t cell engagers
AU2023241306B2 (en) * 2022-10-05 2024-10-03 Tscan Therapeutics, Inc. Prame immunogenic peptides, binding proteins recognizing prame immunogenic peptides, and uses thereof
EP4598569A1 (en) * 2022-10-05 2025-08-13 Tscan Therapeutics, Inc. Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
AU2023409398A1 (en) 2022-12-22 2025-06-05 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
AU2024252725A1 (en) 2023-04-11 2025-11-06 Gilead Sciences, Inc. Kras modulating compounds
CR20250446A (en) 2023-04-21 2025-12-02 Gilead Sciences Inc PRMT5 INHIBITORS AND THEIR USES
AU2024306338A1 (en) 2023-06-30 2026-01-08 Gilead Sciences, Inc. Kras modulating compounds
CN121620513A (en) 2023-07-26 2026-03-06 吉利德科学公司 PARP7 inhibitors
KR20260046403A (en) 2023-07-26 2026-04-07 길리애드 사이언시즈, 인코포레이티드 PARP7 inhibitor
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000502079A (en) * 1995-12-08 2000-02-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Monocyclic .BETA.-lactam derivatives for the treatment of atherosclerosis
US7521197B2 (en) 1998-06-05 2009-04-21 Alexis Biotech Limited Method for producing cytotoxic T-cells
WO2000020445A2 (en) 1998-10-02 2000-04-13 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
US7157091B1 (en) 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
IL160359A0 (en) 2001-08-31 2004-07-25 Avidex Ltd Soluble t cell receptor
KR100467944B1 (en) 2002-07-15 2005-01-24 엘지.필립스 엘시디 주식회사 Transflective Liquid Crystal Display Device and Method for fabricating the same
RU2355703C2 (en) 2002-10-09 2009-05-20 Медиджен Лимитед Single-strand recombinant t-cell receptors
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances
JP5276846B2 (en) 2005-09-13 2013-08-28 国立大学法人三重大学 Vector having nucleic acid encoding T cell receptor inserted therein and cell expressing said receptor
US20120009162A1 (en) * 2009-04-03 2012-01-12 Masaki Yasukawa T cell receptor and nucleic acid encoding the receptor
HRP20171164T1 (en) 2010-09-20 2017-10-20 Biontech Cell & Gene Therapies Gmbh ANTIGEN-SPECIFIC T CELL RECEPTORS AND T CELL EPITOPES
WO2012054825A1 (en) 2010-10-22 2012-04-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mage-a3 t cell receptors and related materials and methods of use
AU2012309830B2 (en) 2011-09-15 2017-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing HLA-A1- or HLA-Cw7-restricted mage
WO2013041865A1 (en) * 2011-09-22 2013-03-28 Immunocore Limited T cell receptors
SG11201400521PA (en) * 2011-10-14 2014-08-28 Teva Pharmaceuticals Australia Pty Ltd ANTIBODIES TO CD1d
KR20150131208A (en) 2013-03-13 2015-11-24 이미지냅 인코포레이티드 Antigen binding constructs to cd8
GB201313377D0 (en) * 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
GB201417803D0 (en) 2014-10-08 2014-11-19 Adaptimmune Ltd T cell receptors
KR102349677B1 (en) 2015-05-28 2022-01-12 카이트 파마 인코포레이티드 How to Condition a Patient for T Cell Therapy
KR20180063320A (en) 2015-10-20 2018-06-11 카이트 파마 인코포레이티드 Methods for producing T cells for T cell therapy
CN106749620B (en) 2016-03-29 2020-09-25 广东香雪精准医疗技术有限公司 T cell receptors that recognize MAGE-A1 antigenic short peptides
KR20190059874A (en) 2016-04-08 2019-05-31 어댑티뮨 리미티드 T cell receptor
DK3440106T3 (en) 2016-04-08 2021-10-04 Adaptimmune Ltd T-CELL RECEPTORS
BR112018070637A2 (en) 2016-04-08 2019-02-05 Adaptimmune Ltd t cell receptors
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
JP7037577B2 (en) 2017-03-15 2022-03-16 フレッド ハッチンソン キャンサー リサーチ センター High affinity MAGE-A1-specific TCR and its use
GB201713078D0 (en) 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
WO2020049496A1 (en) 2018-09-05 2020-03-12 Glaxosmithkline Intellectual Property Development Limited T cell modification

Also Published As

Publication number Publication date
BR112018070625A2 (en) 2019-02-05
US20250084146A1 (en) 2025-03-13
DK3440106T3 (en) 2021-10-04
US20230028573A1 (en) 2023-01-26
RU2018138838A (en) 2020-05-14
AU2017248122B2 (en) 2022-07-21
US11286289B2 (en) 2022-03-29
ZA202006432B (en) 2025-03-26
AU2022256177A1 (en) 2022-11-24
JP2019513383A (en) 2019-05-30
AU2022256177B2 (en) 2025-03-20
KR102523449B1 (en) 2023-04-19
CY1124664T1 (en) 2022-07-22
KR20230044016A (en) 2023-03-31
ZA201806866B (en) 2021-04-28
LT3440106T (en) 2021-12-10
IL262128B1 (en) 2025-07-01
IL262128A (en) 2018-11-29
HRP20211493T1 (en) 2022-01-21
EP3988565A1 (en) 2022-04-27
JP7240176B2 (en) 2023-03-15
SG11201808751SA (en) 2018-11-29
WO2017174824A1 (en) 2017-10-12
EP3440106A1 (en) 2019-02-13
US20220031753A1 (en) 2022-02-03
US11572400B1 (en) 2023-02-07
CN109476725A (en) 2019-03-15
MX2022011309A (en) 2022-10-07
SI3440106T1 (en) 2022-02-28
CN116217703A (en) 2023-06-06
NZ747974A (en) 2024-12-20
KR20190065190A (en) 2019-06-11
MX2018012269A (en) 2019-05-30
JP2023081949A (en) 2023-06-13
PT3440106T (en) 2021-09-29
RU2018138838A3 (en) 2020-07-30
JP7577149B2 (en) 2024-11-01
CN109476725B (en) 2023-04-04
US20190127436A1 (en) 2019-05-02
ES2891321T3 (en) 2022-01-27
RS62623B1 (en) 2021-12-31
HUE056433T2 (en) 2022-02-28
US12180260B2 (en) 2024-12-31
CA3020058A1 (en) 2017-10-12
MX395611B (en) 2025-03-25
IL262128B2 (en) 2025-11-01
EP3440106B1 (en) 2021-09-01
US20240218043A1 (en) 2024-07-04
US11725040B2 (en) 2023-08-15
KR102747867B1 (en) 2024-12-30
AU2017248122A1 (en) 2018-11-22
SMT202100564T1 (en) 2022-01-10

Similar Documents

Publication Publication Date Title
IL264425B1 (en) Anti-kras-g12d t cell receptors
ZA201806866B (en) T cell receptors
ZA201806862B (en) T cell receptors
ZA201806865B (en) T cell receptors
IL262144A (en) T cell receptors
PL4219542T3 (en) T cell receptors
ZA201701823B (en) T cell receptors
GB201522592D0 (en) T cell receptors
SG11201704155UA (en) Anti-mutated kras t cell receptors
SG11201708313QA (en) T cell receptor
PT3433270T (en) T cell receptors
GB201603372D0 (en) Cell
PL3529267T3 (en) T cell receptor
GB201609604D0 (en) Cell
HK40089237A (en) Anti-kras-g12d t cell receptors
GB201518991D0 (en) T cell receptors
HK1238270A1 (en) T cell receptors